Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase NA 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Sinus 1Hematologic Neoplasms 1Erdheim-Chester Disease 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × 68Ga-pentixafor × 1 year × Clear all
NCT05093335 2026-02-05

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
LymphoidMyeloidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Histiocytosis, Sinus, Erdheim-Chester Disease

NCT03335670 2025-07-14

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05255926 2025-06-26

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

Zhongnan Hospital

Phase NA Recruiting
300 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡